CD274 and neoplasm: Recent studies showed that PD-L1 expression, tumor mutational burden and tumor immune microenvironment can be used as predictive biomarkers to predict the response of ICIs treatment, but these require not only invasive procedures to obtain tissue specimens, but also time-consuming and expensive laboratory tests [7, 30].